文献速递糖尿病肥胖与代谢综合征

美国50州糖尿病果蔬处方(PRx)的健康经济影响与成本效果:微观模拟研究

Health and Economic Impact and Cost-effectiveness of Produce Prescriptions for Diabetes in 50 U.S. States: A Microsimulation Study.
PubMed 文献 · Diabetes Care · 2025-01-01

该微观模拟研究评估了在美国50个州为40-79岁同时患有糖尿病和食物不安全成人实施果蔬处方(PRx)项目在5年和10年内的健康与经济影响。结果显示PRx可减少心血管事件、增加质量调整生命年(QALY),在43个州净节约成本,在所有州均具成本效果。

要点

  • PRx在43/50州净节约成本,全部州成本效果比<$150,000/QALY。
  • 10年内每州可避免94-9,240例心血管事件,获得92.2-9,990 QALY。
  • 按保险类型,PRx对Medicare受益人最可能节约成本,其次Medicaid和商业保险。

核心结论

  • 对糖尿病合并食物不安全患者实施PRx可显著改善健康,并在所有美国州均具成本节约或成本效果。

研究设计与样本

  • 使用经验证的微观模拟模型,纳入州特异性数据、20个PRx项目的干预效应与成本、饮食-疾病关联及按支付方划分的医疗支出。
  • 模拟对象为美国各州40-79岁同时患糖尿病和食物不安全的成人,时间跨度5年和10年,成本和结局按3%年贴现率贴现,并进行概率敏感性分析。

主要发现

  • 符合PRx条件的成人数量从加利福尼亚州的约693,000人到怀俄明州的7,000人不等。
  • 10年内,PRx预计在德克萨斯州避免9,240例心血管事件(95% UI 4,710-14,500),在阿拉斯加州避免94例(95% UI 48-147)。
  • 10年内,各州获得的QALY从92.2(95% UI -30.8至159)到9,990(95% UI 4,810-15,500)不等。
  • 从医疗保健角度看,PRx在50州中的43州净节约成本,在所有州均具成本效果(增量成本效果比<$150,000/QALY)。

关键数值与推荐

  • PRx在43/50州净节约成本,全部州增量成本效果比<$150,000/QALY。
  • 10年内心血管事件避免范围94-9,240例,QALY增益范围92.2-9,990。

临床怎么用

  • 支持在糖尿病合并食物不安全成人中推广PRx,尤其优先覆盖Medicare受益人。
  • 各州可根据本地 eligibile 人群规模和支付方结构评估预算影响,纽约等州可能节约更多。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Produce prescription (PRx) programs have been shown to result in improved dietary quality, diabetes control, and cardiometabolic outcomes. However, their potential health and economic impacts across 50 U.S. states, where Medicaid and commercial plans determine coverage, are unclear. RESEARCH DESIGN AND METHODS: Using a validated microsimulation model, we projected the health and economic outcomes of implementing PRx for adults aged 40-79 years with both diabetes and food insecurity in each U.S. state, over 5- and 10-year horizons. The model incorporated state-specific data, pooled intervention effects and costs from 20 PRx programs, diet-disease associations, and payer-specific health care expenditures. Outcomes and costs were discounted at 3% annually. Probabilistic sensitivity analyses accounted for uncertainty. RESULTS: An estimated 693,000 adults in California to 7,000 in Wyoming were eligible for PRx. Over 10 years, PRx was projected to avert between 9,240 cardiovascular disease (CVD) events (95% uncertainty interval [UI] 4,710-14,500) in Texas and 94 (95% UI 48-147) in Alaska and gain 9,990 (95% UI 4,810-15,500) to 92.2 (95% UI -30.8 to 159) quality-adjusted life-years (QALYs) across states. From a health care perspective, PRx was projected to be net cost-saving in 43 of 50 states and was cost-effective (incremental cost-effectiveness ratio <$150,000/QALY) in all, with New York having the largest net saving ($345 million) and California the largest net costs ($155 million). By insurance type, PRx was most likely to be cost-saving for Medicare beneficiaries, followed by Medicaid and private payers. Similar patterns were observed over 5 years. CONCLUSIONS: PRx for patients with diabetes and food insecurity could substantially improve health and be cost saving or cost-effective in all U.S. states.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Wang L, Cudhea F, Deng S, et al. Health and Economic Impact and Cost-effectiveness of Produce Prescriptions for Diabetes in 50 U.S. States: A Microsimulation Study. Diabetes Care. 2025. PMID: 40767914. doi:10.2337/dc25-0144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。